MDT-AP-1183
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 30
- os_event
- false
- age_years
- 11
- sex
- F
- new_clusters
- C6
- umap1_2d
- 4.069137896
- umap2_2d
- 7.001309816
- umap1_3d
- 2.744952413
- umap2_3d
- -0.485428234
- umap3_3d
- -4.399695763
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- DNA_REPAIR+0.390
- PROTEIN_SECRETION+0.350
- OXIDATIVE_PHOSPHORYLATION+0.320
- ADIPOGENESIS+0.130
- FATTY_ACID_METABOLISM+0.130
- HEME_METABOLISM+0.120
- PI3K_AKT_MTOR_SIGNALING+0.120
- NOTCH_SIGNALING+0.080
- BILE_ACID_METABOLISM+0.060
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.040
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.420
- G2M_CHECKPOINT-0.400
- E2F_TARGETS-0.340
- MYC_TARGETS_V2-0.310
- UV_RESPONSE_DN-0.310
- ANDROGEN_RESPONSE-0.280
- ANGIOGENESIS-0.240
- INFLAMMATORY_RESPONSE-0.240
- MTORC1_SIGNALING-0.240
- HYPOXIA-0.220
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_DFWFBYSN | Med | Medulloblastoma | 0.856 |
| 2 | MDT-AP-1158 | Med | Medulloblastoma | 0.855 |
| 3 | MDT-AP-0402 | Med | Medulloblastoma | 0.852 |
| 4 | MDT-AP-0397 | Med | Medulloblastoma | 0.843 |
| 5 | MDT-AP-0372 | Med | Medulloblastoma | 0.842 |
| 6 | MDT-AP-0405 | Med | Medulloblastoma | 0.835 |
| 7 | TCGA-D8-A1JN-01A-11R-A13Q-07 | — | C | 0.833 |
| 8 | TCGA-AO-A12H-01A-11R-A115-07 | — | B | 0.822 |
| 9 | MDT-AP-1354 | Med | Medulloblastoma | 0.812 |
| 10 | BS_HC44ZA0V | Supratentorial Ependymoma | — | 0.812 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 12 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| DNA_REPAIR | 0.390 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.350 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.320 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.130 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.130 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.120 | Temsirolimus | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.120 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.080 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.060 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.040 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.040 | Inavolisib | — uncovered |
| PEROXISOME | 0.030 | Idelalisib | — uncovered |